Background: Microalbuminuria (MA) is associated with increased cardiovascular risk and lipid abnormalities in people with type 2 diabetes. ACE inhibitors and calcium channel blockers (CCBs) reduce MA and are neutral on total cholesterol and triglycerides. The effect of ACE inhibitors and CCBs on lipid subfractions such as Lp(a), apolipoprotein (apo) A1, apo B, and others, however, is unclear. The current study tests the hypothesis that a fixed-dose combination of an ACE inhibitor, benazepril (B) with the dihydropyridine CCB, amlodipine (A), will further reduce arterial pressure and reduce atherogenic lipid fractions compared to either agent alone. Design: A multicentre, randomised, open-label, parallel group design was used to study 27 participants with type 2 diabetes. Measurements for total cholesterol, high-and low-density lipoprotein (HDL and LDL), triglycerides, apo A1, apo B, Lp(a), MA, arterial pressure and creatinine clearance were obtained at baseline and at 12-week intervals during the 36 week study. Results: Arterial pressure was significantly reduced at 36 weeks in all three groups (P ‫؍‬ 0.0078 for A, P ‫؍‬
Introduction
Over the past few years the management of hypertension has focused on the need for an integrated approach to reduce overall cardiovascular risk in diabetes. 1 In contrast to previous approaches that focused solely on reduction of elevated arterial pressure, it is now readily apparent that hypertension is accompanied by a widespread metabolic disarray including dyslipidaemia as part of the 'metabolic syndrome'. [2] [3] [4] Indeed, recent national guidelines have emphasised the importance of not only lowering arterial pressure, but also correcting dyslipidaemia to reduce cardiovascular risk in the diabetic patient. 1, 5 Thus, at the very least, antihypertensive therapy should not exacerbate pre-existing dyslipidaemia, since this may tend to offset the maximum cardiovascular risk reduction documented by arterial pressure lowering.
Some studies note that hypertensive diabetic participants with microalbuminuria (MA) have reduced levels of high-density lipoprotein (HDL)-cholesterol, elevated triglyceride concentrations, increased lowdensity lipoprotein (LDL)-cholesterol and apolipoprotein (apo) B values compared to those without MA. [6] [7] [8] In addition, persons with dyslipidaemia frequently have increased levels of atherogenic small dense LDL and cholesterol-rich remnant lipoproteins. [9] [10] [11] Hence, MA may signal the presence of lipoprotein abnormalities that could play an important role in the increased risk of atherosclerosis.
Clinical studies demonstrate that the LDL component of cholesterol may affect membrane permeability and lead to development of MA. 12, 13 Recent studies also suggest that MA signals the presence of endothelial dysfunction.
14 ACE inhibitors, HMG-Co-A reductase inhibitors and calcium channel blockers (CCBs) have all been shown to reduce MA. 1, 15, 16 Moreover, in a recent meta-analysis, it was noted that lipid-lowering agents reduce albuminuria and help stabilise reduction in renal function. 16 Thus, both blood pressure and lipid reductions are associated with attenuated increases in MA. The relationship between cholesterol sub-fractions (Lipoprotein (a) (Lp(a)), apo-A1, apo-B and HDL-, LDL-cholesterol) and MA reduction has not been previously examined.
The basis for the lipoprotein changes that occur in subjects with MA is unclear, but both dyslipidaemia and MA are associated with insulin resistance. 17 Moreover, an association exists between insulin resistance and small dense LDL-cholesterol. 18 Antihypertensive agents that reduce MA such as ACE inhibitors may have insulin-sensitising properties and others such as CCBs are neutral on insulin sensitivity. [19] [20] [21] An unanswered question, however, is whether the reduction in MA that results from pharmacological treatment is associated with an improvement in lipid and lipoprotein levels. Studies with antihypertensive agents such as betablockers and higher dose diuretics demonstrate detrimental influences on lipoprotein metabolism. 22, 23 The adverse effects on lipoprotein metabolism by these agents could obscure any beneficial effect on lipid levels resulting from treatment of MA.
Several studies have examined the effects of CCBs and ACE inhibitors on lipid metabolism in cellular systems as well as in man. [24] [25] [26] [27] These agents are widely used for the treatment of hypertension and heart disease. Whereas their effects on total cholesterol and triglycerides are known, their effects on cholesterol subfractions is poorly documented. Given that both ACE inhibitors and CCBs are either neutral or reduce insulin resistance and MA, it is possible, that in combination, they will have additive benefits on both lipid subfractions and blood pressure lowering. The current pilot study examines the interaction between concomitant changes in arterial pressure reduction, levels of lipid subfractions and changes in MA. It tests the hypothesis that the combination of an ACE inhibitor with a CCB, in similar dosages to those given individually, will improve lipid subtractions and reduce both blood pressure and MA to a greater extent than either agent alone.
Materials and methods
The study implemented a randomised, two-centre, open label, parallel group design that involved randomisation to either an ACE inhibitor, benazepril (10 mg/d), a CCB, amlodipine (5 mg/d) or the combination of the two in the same dosages. The illustrated protocol in Figure 1 outlines the study design and procedures carried out during the study. In brief, all participants had their antihypertensive medication stopped for 2 weeks prior to randomisation. Those who had a diastolic blood pressure above 115 mm Hg within the 2-week washout period were excluded from the study. During the 8-month maintenance period, participants had assessments of blood pressure, lipid subfractions including total cholesterol and triglycerides, fasting glucose, creatinine clearance and microalbuminuria, at various visits ( Figure 1 ). Total cholesterol and triglycerides were measured by standard enzymatic kit methods (Roche, Basel, Switzerland) on the COBAS Mira analyzer. HDL-cholesterol was measured after precipitation of apo B-containing lipoproteins using dextran sulfate and magnesium chloride, and HDL2 and HDL3 subfractions separated by differential precipitation. 28 LDL-cholesterol was calculated according to Friedewald et al. 29 Apo A-l, and apo B were measured by immunoturbidometric methods (Incstar, Stillwater, MN, USA) on the COBAS analyzer, and Lp(a) was assayed using an ELISA (Perlmmune). LDL particle size was measured by non-denaturing polyacrylamide gels electrophoresis 30 and HbA1c was assayed by a standard high pressure liquid chromatographic method (Biorad Labs, Hercules, CA, USA).
Participants were selected from screening through chart review of laboratory data, medical history, recent physical exam findings, and current medical status. Forty-six men and women were screened for the study, 27 met the inclusion and exclusion criteria for the study. Twenty-four of the 27 participants (89%) completed the study. Those who had a diastolic arterial pressure above 115 mm Hg within the 2-week washout period were excluded from the study. The remaining participants were randomised in a 1:1:1 fashion to either benazepril 10 mg/d or amlodipine 5 mg/d or the combination of benazepril plus amlodipine (10/5 mg/d) following the 2-week washout period.
All individuals were scheduled for a screening visit. The study was discussed and the participant given a consent in order to discuss the study participation with their primary health care provider. At visit one, all participants signed the consent form approved by the Rush or University of Miami Institutional Review Boards and entered into the study. Two weeks after the initial visit, the participants returned for the baseline exam. At this time, any questions regarding the study were addressed.
Additionally, a complete medical history and physical exam was performed as well as a review of the inclusion/exclusion criteria. The inclusion criteria for the study included: (a) presence of type 2 diabetes documented by medical history; (b) average sitting diastolic arterial pressure (Korotkoff phase V) Ͼ90 mm Hg and Ͻ115 mm Hg (determined from an average of three consecutive readings taken 2 min apart); (c) off medications for 2 to 4 weeks; (d) urinary albumin excretion Ͼ50 mg/day; (e) serum triglycerides Ͻ350 mg/dl; and (f) age у40 years.
Participants were excluded who did not meet these criteria. Additionally, they were excluded if one of the following criteria were met: (a) women of child bearing potential; (b) had a serum creatinine of Ͼ2.0 mg/dl or calculated creatinine clearance of less than 40 ml per minute; (c) cerebral vascular accident, convulsive disorder, or episode of hypertensive encephalopathy within the previous year; (d) clinically significant congestive heart failure or suspicion or evidence (ejection fraction Ͻ40%) of serious cardiac decompensation, severe bradycardia (less than 50 beats per minute) clinically significant cardiac dysrhythmias, evidence of sinus node dysfunction, abnormal sinoatrial, atrioventricular or intraventricular conduction abnormalities, firstdegree AV block was allowed; (e) history of myocardial infarction within the previous 3 months; (f) known hypersensitivity or history of serious adverse reactions (ie, angioedema) or intolerance to calcium channel blocking drugs or ACE inhibitors; (g) clinically significant hepatic dysfunction as determined by liver function tests, ie, bilirubin Ͼ2 mg %, SGOT and/or SGPT and/or alkaline phosphatase more than twice the upper limit of normal; (h) clinically significant electrolyte imbalance (serum potassium Ͻ3.5 mmol per litre or Ͼ5.5 mEq per litre, serum sodium Ͻ132 mmol per litre; (i) clinically significant haematological abnormalities; (j) any medical or surgical condition (eg, gastrectomy) which might
Journal of Human Hypertension interfere with drug absorption, metabolism or excretion; (k) those on lipid-lowering agents; (l) participation in another investigational drug study during the 30 days preceding study entry; (m) history of chronic alcohol or drug abuse or dependence during the past 2 years; chronic use of barbituates within the past 30 days; (n) terminal illness; and (o) inability to safely discontinue use of the following prior to entering the placebo run-in period m ACE inhibitors, CCBs, antiarrythmic drugs, digitalis glycosides, monoamine oxidase (MAO) inhibitors, psychotropic drugs such as major tranquilizers, antidepressants, central nervous system stimulants and depressants, any medications containing phenylpropanolamine or pseudoephedrine (ie, all nasal decongestants, diet aids, and bronchodilators), acute or chronic drug administration of non-steroidal antiinflammatory drugs or analgesics except aspirin 325 mg or less daily.
At the time of randomisation, all participants had blood pressure, heart rate and body weight assessed. Additionally, they had fasting glucose, lipid and blood chemistry tests that included, lipid subfractions, creatinine and haemoglobin A1c. All analyses for lipid subfractions including HDL and Lp(a) were run using the same assay to avoid intraassay variability. Twenty-four hour urines were also collected to assess albumin and creatinine levels. Participants also received dietary counseling regarding high sodium intake, salt substitutes and instructed to avoid such substances during the study. They were instructed and encouraged to follow a Ͻ120 mEq per day sodium diet.
Participants were randomised and instructed to take one capsule or tablet each morning at approximately 9.00 am. Participants were maintained on this medication for 9 months. Participants were dropped from the study if their systolic arterial pressure could not be reduced to less than 180 mm Hg or their diastolic arterial pressure below 100 mm Hg while on randomised drug. During the randomisation period, if arterial pressure was not controlled to a level of Ͻ140/90 mm Hg, hydrochlorothiazide (12.5 mg) was added as a second agent.
Statistical analysis
In total, 27 patients were randomised, eight patients were successfully randomised to the benazepril arm, 12 to the amlodipine arm, and seven to the combination arm. Because of the small sample size, care was taken to choose appropriate statistical procedures to obviate confounding. Many statistical procedures have properties that are based on the assumption that the sample size is much larger than is present in the current study. Nonparametric statistical analysis procedures, however, have properties that are not based on large sample results and, thus, not overly sensitive in small samples. Thus, where appropriate, nonparametric procedures were used. This is made clear, by providing confidence interval for median data where non-parametric statistical analyses were used, otherwise, mean values were used and parametric statistics performed. The Kruskal-Wallis test was used to compare average values between the three treatment groups. Individual effects of the three treatments were assessed by testing whether the median post-treatment (36 week) values were significantly different from the median baseline values using Wilcoxon signed rank tests. Individual effects were then compared between the three groups using the KruskalWallis tests. Correlations were assessed using Pearson correlation coefficients.
Results
Twenty-four patients completed the stated protocol and their data used for this analysis. Of these 24, 11 were women and 13 were men. Age ranged from 38 years to 73 years. Table 1 summarises the demographic data for these patients by treatment group. No statistical differences were observed between groups with regards to any baseline demographic or biochemical data.
Median baseline and post-treatment (36 week) values for lipid subfractions, fasting blood glucose, blood pressure and renal function are presented in Table 2 . While there were no significant differences among the median baseline values of arterial pressure, all three groups had significantly lower values at 36 weeks (P ϭ 0.0078 for A, P ϭ 0.0039 for B, and P ϭ 0.0313 for AϩB) ( Table 2) . While, the difference in magnitude of arterial pressure reduction did not differ significantly between the B and AϩB groups (P Ͼ 0.3), the combination group provided a significantly greater reduction in systolic pressure compared to A alone (−23 ± 3 ⌬mmHg, A alone vs −32 ± 4 ⌬mmHg, AϩB; P Ͻ 0.05) Increases in HDL-cholesterol were seen in both the B and AϩB groups ( Table 2 ). All groups also demonstrated significant reductions in MA values (P ϭ 0.0039), from baseline, with the B and AϩB groups showing relatively greater reductions than A Data represent mean ± standard error; AA, African-American. alone ( Figure 2 ). Moreover, a trend was observed between the reduction in MA and the rise in HDLcholesterol across all groups, but was most pronounced, albeit not significant, for the AϩB group (P ϭ 0.06).
Apo A1 decreased significantly in the group randomised to A alone but was not affected in either of the other groups. Moreover, HDL2 and HDL3 subfraction concentrations did not change (Table 2) . Additionally, a significant effect was seen on the median change in Lp(a). Benazepril decreased the median value of Lp(a), while no change was noted in the other groups (Table 2 ). However, the percent decrease in Lp(a) and increase in HDL from baseline in both the B and AϩB groups were significantly different compared to A alone (Figure 3 ). There was no difference in LDL-cholesterol, LDL-particle size or in the LDL-cholesterol/apo B ratio in any of the groups at study termination. However, the LDLcholesterol/apo B ratio in the AϩB group changed the least from baseline compared to either group alone (−1.45, A alone vs 0.09 B alone vs 0.01; P ϭ 0.03). None of the other comparisons of median values were statistically different. Blood pressure reduction or reductions in MA did not correlate in any group with changes in Lp(a), A (P ϭ 0.09), B (P ϭ 0.38) and AϩB (P ϭ 0.41).
Lastly, MA was significantly reduced in all groups at 36 weeks from baseline ( Figure 2) . However, the greatest reductions from baseline were seen in the benazepril (73.6 ± 13% B vs 35.3 ± 12% A; P Ͻ 0.001) and AϩB groups (61.6 ± 17% B vs 35.3 ± 12% A; P Ͻ 0.01) compared with A alone. All groups showed a correlation between the magnitude of blood pressure reduction and albuminuria reduction. The magnitude of MA reduction correlated with the magnitude of blood pressure reduction to the greatest degree in the A group (r ϭ 0.31; P ϭ 0.02) while the other groups did not correlate to the same degree, B group (r ϭ 0.18; P ϭ 0.06) and AϩB (r ϭ 0.22; P ϭ 0.04).
Discussion
Data from this trial both confirm and extend the results of previous studies that examined the effects of these classes of antihypertensive agents on total cholesterol and triglycerides. We confirm previous reports of neutral effects on total cholesterol and triglycerides with both the ACE inhibitor and CCB. [31] [32] [33] We also corroborate a previous report that indicated small increases in HDL-cholesterol with an ACE inhibitor. 34 More importantly, we noted, that HDLcholesterol also rose with the use of the ACE inhibitor/CCB combination. Those who received the ACE inhibitor/CCB combination showed no associated changes in HDL2, HDL3 or in the HDLcholesterol/apo A-l ratio suggesting that this increase occurred without a significant change in HDL composition. Additionally, we extend the previously published data by demonstrating a relation- 
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ship between HDL-cholesterol increases and reductions in MA levels with the combination of an ACE inhibitor/CCB. Lastly, we were unable to detect any deleterious changes in levels of apo B, LDLcholesterol, LDL particle size, or in the LDLcholesterol/apo B ratio with either the ACE inhibitor or CCB. These data, taken together with previous findings, indicate that an ACE inhibitor with a CCB, given comparable levels of arterial pressure reduction, yield a lipid subfraction profile comparable to the ACE inhibitor used alone.
Our data indicate that certain lipid subfractions such as Lp(a) and HDL-cholesterol are positively influenced by either an ACE inhibition alone or with an ACE inhibitor/CCB combination but not a dihydropyridine CCB alone. Moreover, the combination offered a significantly greater reduction in blood pressure from baseline compared to A alone. Given that it takes an average of three different antihypertensive drugs to achieve the blood pressure goals recommended by most guidelines, the AϩB combination becomes a desirable agent in the highrisk patient such as those with renal insufficiency. 1 Several lines of evidence indicate that increases in Lp(a) are associated with increased CV risk. 35, 36 In addition, Lp(a) levels are known to be increased in subjects with renal failure as well as in type 1 diabetes, but not in subjects with type 2 diabetes. 37, 38 The reports regarding the effect of ACE inhibitors on Lp(a) are mixed. Some reports have not demonstrated an increase with ACE inhibitors and others have. [39] [40] [41] Our data corroborate the fact that ACE inhibitors do reduce Lp(a) levels in people with renal insufficiency.
While many cholesterol subfractions have been implicated in contributing to renal dysfunction, HDL-cholesterol and Lp(a) have been distinguished as having a greater role in this context. Low HDLcholesterol has been described as an independent risk factor for renal disease progression in a community-based study. 42 The mechanism for this is unclear but may relate to the tissue protective effects or stabilisation of prostacyclin metabolism noted with high levels of HDL-cholesterol or increased oxidative stress in vascular tissue associated with Lp(a). 11, 43, 44 Alternatively, it could be related to the fact that a reduction in HDL is a marker of the acute-phase response with which MA may be associated. 45 Our data support the concept that ACE inhibition either alone or in combination with a CCB, if needed to achieve the blood pressure goal, might help improve this aforementioned lipid profile.
Over a decade of clinical studies in people with diabetes link reduction in MA to both a slowed progression in renal disease in type 1 diabetes and reduction in CV events. [46] [47] [48] [49] Our data demonstrates that use of an ACE inhibitor in combination with a CCB may reduce cardiovascular risk by not only reducing arterial pressure and MA but indirectly by impacting on HDL-cholesterol. Given the positive metabolic profile, impact on MA, and that the majority of people with renal disease and/or diabetes require two or more medications to achieve an arterial pressure goal of Ͻ130/80 mm Hg, our study supports the use of this combination in the setting. 1 Finally, the purpose of this pilot study was to generate data to support the hypothesis that an ACE inhibitor in combination with a CCB improves lipid profiles. We provide such data, however, this study clearly has limitations, including a small sample size and lack of a placebo control group. Clearly, a larger scale trial needs to be performed to confirm such results.
